title: Systemic Therapy for Advanced Soft Tissue Sarcoma.
abstract: Soft tissue sarcomas are rare tumors that present with distant metastasis in up to 10% of patients. Survival has improved significantly because of advancements in histologic classification and improved management approaches. Older agents such as doxorubicin, ifosfamide, gemcitabine, and paclitaxel continue to demonstrate objective response rates from 18% to 25%. Newer agents such as trabectedin, eribulin, aldoxorubicin, and olaratumab have demonstrated improvements in progression-free survival, overall survival, or toxicity profiles. Future studies on treatment of advanced soft tissue sarcoma will continue to concentrate on reducing toxicity, personalization of therapy, and targeting novel pathways.
authors.affiliation: Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: jsheng7@jhmi.edu.
authors.forename: Jennifer Y
authors.initials: JY
authors.lastname: Sheng
authors.affiliation: Department of Hematology/Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA.
authors.forename: Sujana
authors.initials: S
authors.lastname: Movva
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019468:Disease Management; D006801:Humans; D012509:Sarcoma / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents
keywords: Advanced soft tissue sarcoma; Chemotherapy; Novel therapies